Depressive- and anxiety-like behaviors were measured in WT and HIV-1 tg rats receiving daily oral dosing of meloxicam.
A,B) In the Porsolt forced swim test, meloxicam treated WT and HIV-1 tg rats showed similar latencies to first float (p>0.05); however, HIV-1 tg rats spent more time immobile compared to WT controls (*p<0.05). C,D) Similarly, in the social interaction test, meloxicam treated WT and HIV-1 tg rats showed no differences in their time to approach a stimulus rat (p>0.05); however, overall, meloxicam-treated HIV-1 tg rats spend less time interacting (*p<0.05). E,F) In the open field test, meloxicam treated HIV-1 tg rats showed no differences in overall locomotion (p>0.05), but did show a significant decrease in distance traveled in the center of the open field, as compared to WT rats (*p<0.05). Data are presented as mean ± SEM.